A drug maker focused on development and commercialization of diabetes treatments unveiled its accelerating clinical development plans of two drug candidates.

A study published last week in Nutrition Journal found that dietary supplement usage and patient recommendations were common for physicians across several medical specialties, including dermatology, cardiology and orthopedics.

Family Dollar reported Monday a comparable-store sales increase of 5.1% for the second quarter ended Feb. 26. Net sales for the quarter increased 8.3% to $2.26 billion, from $2.09 billion last year. According to the retailer, warmer weather earlier in the year, as well as strong performance in its consumables and seasonal categories, helped drive sales.

Drug maker Gilead acknowledged the receipt of an unsolicited mini-tender offer by TRC Capital.

A Midwest retailer announced it would invest $75 million in a major remodel project that would benefit stores in two states.

New Chapter last week introduced a slew of new products at the Natural Products Expo West in Anaheim, Calif., including three fish oil supplements and two multivitamins.

By 2015, “pharmacists will be the healthcare professionals responsible for providing patient care that ensures optimal medication therapy outcomes.” That was the consensus reached in the Joint Commission of Pharmacy Practitioners' vision statement at the Pharmacy Technician Certification Board’s Consumer Awareness, Resources, Education, State Policy and Testing Summit last month.

Beiersdorf, whose brands include Nivea, Eucerin and Aquaphor, has announced that Robert Taylor-Hughes, president of Beiersdorf North America, is leaving the company.

As part of its 90th anniversary celebration, Wonder bread is gearing up to launch a campaign to honor America's everyday heroes.

A new line of organic and Fair Trade-certified chocolate bars has hit the market.

Specialty pharmacy provider BioScrip had sales of $450.4 million in fourth quarter 2010 and $1.6 billion for the year as a whole, according to financial results released Friday.

The Food and Drug Administration has approved biotech company Dendreon’s expansion of manufacturing capacity for an immunotherapy treatment for prostate cancer, Dendreon said Thursday.